Journal
BIOTECHNOLOGY JOURNAL
Volume 16, Issue 1, Pages -Publisher
WILEY-V C H VERLAG GMBH
DOI: 10.1002/biot.202000025
Keywords
Adeno-associated virus; gene therapy; manufacturing; viral vector
Funding
- MYOCURE project
- European Union's Horizon 2020 research and innovation program [667751]
- German Center for Infection Research (DZIF, BMBF) [TTU-HIV 04.803, TTUHIV 04.815]
- German Research Foundation (DFG) through the Cluster of Excellence CellNetworks [EXC81]
- German Research Foundation (DFG) through the Collaborative Research Centers [SFB1129, 240245660, TRR179, 272983813]
- Projekt DEAL
- H2020 Societal Challenges Programme [667751] Funding Source: H2020 Societal Challenges Programme
Ask authors/readers for more resources
Over the past two decades, gene therapy vectors based on wild-type AAV have proven safe and effective in clinical trials, while engineered synthetic AAV capsids show promising potential. There is a growing demand for new processes to accommodate the expanding range of AAV capsid variants.
Over the last two decades, gene therapy vectors based on wild-type Adeno-associated viruses (AAV) are safe and efficacious in numerous clinical trials and are translated into three approved gene therapy products. Concomitantly, a large body of preclinical work has illustrated the power and potential of engineered synthetic AAV capsids that often excel in terms of an organ or cell specificity, the efficiency of in vitro or in vivo gene transfer, and/or reactivity with anti-AAV immune responses. In turn, this has created a demand for new, scalable, easy-to-implement, and plug-and-play platform processes that are compatible with the rapidly increasing range of AAV capsid variants. Here, the focus is on recent advances in methodologies for downstream processing and characterization of natural or synthetic AAV vectors, comprising different chromatography techniques and thermostability measurements. To illustrate the breadth of this portfolio, two chimeric capsids are used as representative examples that are derived through forward- or backwards-directed molecular evolution, namely, AAV-DJ and Anc80. Collectively, this ever-expanding arsenal of technologies promises to facilitate the development of the next AAV vector generation derived from synthetic capsids and to accelerate their manufacturing, and to thus boost the field of human gene therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available